CRIZALK (Crizotinib)-250mg

CRIZALK (Crizotinib) works by targeting and blocking receptors found on the cancer cells called an anaplastic lymphoma kinase (ALK). In some cancers, this receptor is overactive, causing cells to grow and divide too fast. By inhibiting ALK, this medication can slow or stop the cell growth of cancer cells.

It is used for the treatment of patients with metastatic Non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK) and ROS1 fusion gene.

Enquiry Now

Additional information

Trade Name

CRIZALK 250mg

Generic Name

Crizotinib

Manufacturer

Pfizer

Drug Type

Oncology

Indication

Lung Cancer

Doasage Form

Capsules

Packaging

60 capsules ( 60 / strip )